Wednesday, 27 January, 2021, 5:15 PM
latest 528 infected, 17 die of COVID in Bangladesh       PM Hasina opens COVID-19 vaccination programme       
Home International

Indian minister tests positive after taking Covid vaccine trial dose

Published : Saturday, 5 December, 2020 at 4:41 PM  Count : 221

Haryana's Health Minister Anil Vij was administered the Covaxin vaccine on November 20. (File Photo)

Haryana's Health Minister Anil Vij was administered the Covaxin vaccine on November 20. (File Photo)


Indian minister Anil Vij tweeted on Saturday morning to say that he has tested positive for coronavirus. Mr Vij, 67, said he is admitted at the Civil Hospital in Ambala. The announcement comes a little over two weeks after he participated in the clinical trials of a coronavirus vaccine.

The Haryana Home Minister also urged all those who had come in close contact with him to get themselves tested, NDTV reports.

"I have been tested Corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona," Mr Vij tweeted.

On November 20, Mr Vij, who is also Haryana's Health Minister, participated in the third phase trial of Bharat Biotech's Covaxin. He had earlier announced on Twitter that he will be the first volunteer in his state for the vaccine trials.

"The antibodies against the infection build up in a human being only after a specific number of days pass after the second dose of the vaccine is taken, since this is a two-dose vaccine. The minister in question has taken only one dose of the vaccine," the Union Health Ministry said after Mr Vij's announcement.

Bharat Biotech, that is developing the vaccine, said the clinical trials of Covaxin are based on a two-dose schedule, given 28 days apart. "The vaccine efficacy will be determined 14 days post the second dose. Covaxin has been designed to be efficacious when subjects receive both doses," the Hyderabad-based drug maker said, reacting to the news of the Haryana minister testing positive.

Covaxin has been evaluated in about 1,000 subjects in the first two phases of clinical trials, with promising safety and immunogenicity data.





"The Phase-3 trials are double-blinded and randomised, where 50% of subjects (participants in the trial) receive vaccine and  50% of subjects receive placebo," the company said.

GY



« PreviousNext »



Latest News
Most Read News
Editor : Iqbal Sobhan Chowdhury
Published by the Editor on behalf of the Observer Ltd. from Globe Printers, 24/A, New Eskaton Road, Ramna, Dhaka.
Editorial, News and Commercial Offices : Aziz Bhaban (2nd floor), 93, Motijheel C/A, Dhaka-1000. Phone: PABX 9586651-58; Online: 9513959; Advertisement: 9513663
E-mail: [email protected], [email protected], [email protected], [email protected],   [ABOUT US]     [CONTACT US]   [AD RATE]   Developed & Maintenance by i2soft